Odevixibat

Odevixibat
Clinical data
Trade names	Bylvay
Other names	A4250
AHFS/Drugs.com	Monograph
MedlinePlus	a621049
License data	US DailyMed: Odevixibat;
Routes of; administration	By mouth
ATC code	A05AX05 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (2S)-2-{[(2R)-2-[({[3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid;
CAS Number	501692-44-0;
PubChem CID	10153627;
IUPHAR/BPS	11194;
DrugBank	DB16261;
ChemSpider	8329135;
UNII	2W150K0UUC;
KEGG	D11716;
ChEMBL	ChEMBL4297588;
CompTox Dashboard (EPA)	DTXSID601336860 ;
Chemical and physical data
Formula	C37H48N4O8S2
Molar mass	740.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C3=CC=C(O)C=C3)C=C2S(=O)(=O)N1;
	InChI InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1; Key:XULSCZPZVQIMFM-IPZQJPLYSA-N;

Odevixibat, sold under the brand name Bylvay among others, is a medication for the treatment of progressive familial intrahepatic cholestasis. It is taken by mouth. Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). It was developed by Albireo Pharma.

The most common side effects include diarrhea, abdominal pain, hemorrhagic diarrhea, soft feces, and hepatomegaly (enlarged liver).

Odevixibat was approved for medical use in the United States and in the European Union in July 2021. The U.S. Food and Drug Administration considers it to be a first-in-class medication.